Roham T Zamanian MD
Critical Care Medicine, Pleural Disease
Assistant Professor, Medicine - Pulmonary & Critical Care Medicine, Stanford University Medical Center
Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Zamanian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2005
University of California (Irvine)Residency, Internal Medicine, 1999 - 2002
University of California, Irvine, School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2027
American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Insulin Resistance in Pulmonary Arterial Hypertension Start of enrollment: 2008 Sep 01
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
- A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil). Start of enrollment: 2010 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR).Eric W Robbins, Kaitlin Bradley, David Badesch, Charles Burger, Amy M Chyboski
Annals of the American Thoracic Society. 2025-06-01 - Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension.Kathryn Czepiel, Nadine Nagy, Tamera Panjalingam, Anissa Kalinowski, Adam R Frymoyer
Thorax. 2025-06-01 - Drugs targeting novel pathways in pulmonary arterial hypertension.Olivier Sitbon, Athénaïs Boucly, Jason Weatherald, Fabrice Antigny, Christophe Guignabert
The European Respiratory Journal. 2025-05-08
Authored Content
- Pulmonary Vascular Fellowship Training to Promote Excellence in PH Clinical Care: The Stanford PerspectiveSeptember 2020
Press Mentions
Halo Biosciences Announces Thorax Publication of Phase 2a SATURN Study Results in PH-ILDJune 4th, 2025- Tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of TiprelestatJanuary 8th, 2025
Hemodynamic Trajectories and Outcomes in Patients with Pulmonary Arterial HypertensionDecember 6th, 2020- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
